These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 20653840)

  • 1. Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA).
    Rose AJ; Hylek EM; Ozonoff A; Ash AS; Reisman JI; Berlowitz DR
    J Thromb Haemost; 2010 Oct; 8(10):2182-91. PubMed ID: 20653840
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pathways to poor anticoagulation control.
    Razouki Z; Ozonoff A; Zhao S; Rose AJ
    J Thromb Haemost; 2014 May; 12(5):628-34. PubMed ID: 24548552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determinants of oral anticoagulation control in new warfarin patients: analysis using data from Clinical Practice Research Datalink.
    Macedo AF; Bell J; McCarron C; Conroy R; Richardson J; Scowcroft A; Sunderland T; Rotheram N
    Thromb Res; 2015 Aug; 136(2):250-60. PubMed ID: 26073321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Warfarin Management and Outcomes in Patients with Nonvalvular Atrial Fibrillation Within an Integrated Health Care System.
    An J; Niu F; Zheng C; Rashid N; Mendes RA; Dills D; Vo L; Singh P; Bruno A; Lang DT; Le PT; Jazdzewski KP; Aranda G
    J Manag Care Spec Pharm; 2017 Jun; 23(6):700-712. PubMed ID: 28530526
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting outcomes among patients with atrial fibrillation and heart failure receiving anticoagulation with warfarin.
    Kim EJ; Ozonoff A; Hylek EM; Berlowitz DR; Ash AS; Miller DR; Zhao S; Reisman JI; Jasuja GK; Rose AJ
    Thromb Haemost; 2015 Jul; 114(1):70-7. PubMed ID: 25948532
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improving quality measurement for anticoagulation: adding international normalized ratio variability to percent time in therapeutic range.
    Razouki Z; Ozonoff A; Zhao S; Jasuja GK; Rose AJ
    Circ Cardiovasc Qual Outcomes; 2014 Sep; 7(5):664-9. PubMed ID: 25185245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk-adjusted percent time in therapeutic range as a quality indicator for outpatient oral anticoagulation: results of the Veterans Affairs Study to Improve Anticoagulation (VARIA).
    Rose AJ; Hylek EM; Ozonoff A; Ash AS; Reisman JI; Berlowitz DR
    Circ Cardiovasc Qual Outcomes; 2011 Jan; 4(1):22-9. PubMed ID: 21098779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. INR targets and site-level anticoagulation control: results from the Veterans AffaiRs Study to Improve Anticoagulation (VARIA).
    Rose AJ; Berlowitz DR; Miller DR; Hylek EM; Ozonoff A; Zhao S; Reisman JI; Ash AS
    J Thromb Haemost; 2012 Apr; 10(4):590-5. PubMed ID: 22288563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. INR goal attainment and oral anticoagulation knowledge of patients enrolled in an anticoagulation clinic in a Veterans Affairs medical center.
    Baker JW; Pierce KL; Ryals CA
    J Manag Care Pharm; 2011 Mar; 17(2):133-42. PubMed ID: 21348546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial.
    Van Spall HG; Wallentin L; Yusuf S; Eikelboom JW; Nieuwlaat R; Yang S; Kabali C; Reilly PA; Ezekowitz MD; Connolly SJ
    Circulation; 2012 Nov; 126(19):2309-16. PubMed ID: 23027801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of oral anticoagulation control in Chinese patients with non-valvular atrial fibrillation: a prospective controlled study.
    Li Y; Yu J; Kuang Y; Wu C; Yang L; Fang Q; Pei Q; Yang G
    Curr Med Res Opin; 2020 Sep; 36(9):1433-1439. PubMed ID: 32677855
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of anticoagulation with warfarin in patients with nonvalvular atrial fibrillation in the community setting.
    Han SY; Palmeri ST; Broderick SH; Hasselblad V; Rendall D; Stevens S; Tenaglia A; Velazquez E; Whellan D; Wagner G; Heitner JF
    J Electrocardiol; 2013; 46(1):45-50. PubMed ID: 23063241
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anticoagulation Control, Outcomes, and Associated Factors in Patients with Atrial Fibrillation Receiving Warfarin at Tertiary Care Hospital in Ethiopia.
    Yimer NS; Abiye AA; Hussen SU; Tadesse TA
    Clin Appl Thromb Hemost; 2021; 27():10760296211049786. PubMed ID: 34724849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identifying potential predictors of high-quality oral anticoagulation assessed by time in therapeutic international normalized ratio range: a prospective, long-term, single-center, observational study.
    Costa GL; Lamego RM; Colosimo EA; Valacio RA; Moreira Mda C
    Clin Ther; 2012 Jul; 34(7):1511-20. PubMed ID: 22717417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identifying the risks of anticoagulation in patients with substance abuse.
    Efird LM; Miller DR; Ash AS; Berlowitz DR; Ozonoff A; Zhao S; Reisman JI; Jasuja GK; Rose AJ
    J Gen Intern Med; 2013 Oct; 28(10):1333-9. PubMed ID: 23620189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reexamining the recommended follow-up interval after obtaining an in-range international normalized ratio value: results from the Veterans Affairs study to improve anticoagulation.
    Rose AJ; Ozonoff A; Berlowitz DR; Ash AS; Reisman JI; Hylek EM
    Chest; 2011 Aug; 140(2):359-365. PubMed ID: 21310837
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes associated with warfarin time in therapeutic range among US veterans with nonvalvular atrial fibrillation.
    Liu S; Li X; Shi Q; Hamilton M; Friend K; Zhao Y; Horblyuk R; Hede S; Shi L
    Curr Med Res Opin; 2018 Mar; 34(3):415-421. PubMed ID: 28945114
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of the Quality of Chronic Anticoagulation Control With Time in Therapeutic Range in Atrial Fibrillation Patients Treated With Vitamin K Antagonists by Hemostasis Specialists: The TERRA Registry: Tiempo en rango en la República Argentina.
    Tajer C; Ceresetto J; Bottaro FJ; Martí A; Casey M;
    Clin Appl Thromb Hemost; 2017 Jul; 23(5):445-453. PubMed ID: 26739542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anticoagulation for stroke prevention in elderly patients with atrial fibrillation, including those with falls and/or early-stage dementia: a single-center, retrospective, observational study.
    Jacobs LG; Billett HH; Freeman K; Dinglas C; Jumaquio L
    Am J Geriatr Pharmacother; 2009 Jun; 7(3):159-66. PubMed ID: 19616184
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Warfarin anticoagulation in hemodialysis patients with atrial fibrillation: comparison of nephrologist-led and anticoagulation clinic-led management.
    Bahbahani H; AlTurki A; Dawas A; Lipman ML
    BMC Nephrol; 2018 Jan; 19(1):4. PubMed ID: 29310600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.